Alexion Pharmaceuticals (ALXN) agreed to pay more than $21 million for maintaining a false set of accounting books in connection with bribes paid to government officials in Russia and Turkey in order to boost use of its most important drug. The settlement also covers inaccurate financial records concerning payments that were made to patient advocacy groups, among others, in Brazil and Colombia.

Between 2010 and 2015, the company paid more than $1.3 million to a consultant in Turkey who used some of the money to bribe government officials to ensure prescriptions for Soliris, a treatment for combatting a rare blood disorder. Not only were the payments recorded inaccurately, but were done in pencil, so the numbers could later be changed, according to an order filed by the Securities and Exchange Commission in federal court.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy